Twist Bioscience earnings date
Want to see TWST full AI Analyst Report?
Twist Bioscience (TWST) Q4 2026 Earnings Report
TWST Q4 2026 EPS Results
- Actual EPS
- -$0.32
- Consensus EPS
- -$0.39
- Beat/Miss
- Beat by +$0.07
- One Year Ago EPS
- -$0.45
TWST Q4 2026 Revenue Results
- Actual Revenue
- $126.64M
- Expected Revenue
- $123.55M
- Beat/Miss
- Beat by +$3.10M
- YoY Revenue Growth
- +27.91%
Earnings Announcement Details
- Quarter
- Q4 2026
- Date
- 11/12/2026
- Time
- Before Open
- Conference Call
- Thursday, November 12, 2026
Twist Bioscience's next earnings date is estimated for January 29, 2027, based on past reporting schedules.
Q4 2026 Earnings Call Audio
Q4 2026 Earnings Slide Deck
Q4 2026 Earnings Call Summary
The call was strongly positive, supported by 28% fourth-quarter revenue growth, 22% full-year growth, gross-margin expansion, positive fourth-quarter adjusted EBITDA, 175% AI drug discovery revenue growth, robust customer and order momentum, strong liquidity and above-20% fiscal 2027 revenue-growth guidance. The principal challenges were the full-year adjusted EBITDA loss, planned investment-related depreciation and manufacturing-cost headwinds, early-stage mRNA revenue, difficulty classifying AI revenue and customer concentration within NGS. Highlights significantly outweighed the lowlights.
For fiscal 2027, Twist expects total revenue of $550 million to $560 million, representing growth of approximately 21% at the midpoint, with revenue growth outlook above 20%; guidance assumes $100 million in AI drug discovery revenue, with a high degree of confidence today and meaningful upside, while the company expects triple-digit percentage growth in orders and revenue for fiscal '27. The company expects sequential growth in DNA synthesis and Protein Solutions and NGS applications throughout the year, gross margin of approximately 52.5% to 53%, positive adjusted EBITDA for the full year and capital expenditures of approximately $75 million, excluding landlord-funded tenant improvements. For the first quarter of fiscal 2027, Twist expects revenue of $130 million to $132 million, representing growth of approximately 26% year-over-year at the midpoint and continued sequential growth for both DSPS and NGS, with each product group growing above 25% year-over-year. Over fiscal 2027 and fiscal 2028, the company expects approximately $150 million in capital expenditures plus more than $30 million in landlord-funded tenant improvements, expanding long-term capacity to support more than $1 billion in annual revenue within its existing facilities at scale.
- Strong Fourth-Quarter and Full-Year Revenue GrowthFourth-quarter revenue was $126.6 million, up 28% year-over-year and 7% sequentially, marking the 15th consecutive quarter of sequential growth. Full-year revenue reached $459.4 million, up 22% from $376.6 million in fiscal 2025 and more than $30 million above initial fiscal 2026 guidance.
- Positive Adjusted EBITDA MilestoneFourth-quarter adjusted EBITDA was positive at $2.2 million, achieving the milestone the company had committed to. Management said this provides more options for operating Twist and intends to reinvest profits in capabilities, capacity and people that can drive top-line growth.
- Gross Margin ExpansionFourth-quarter gross margin was 53.1%, compared with 51.3% a year ago. Full-year gross margin was 52.4%, compared with 50.7% in fiscal 2025.
- Long-Term Revenue Growth Track RecordOver the last three years, revenue grew at a compound annual rate of 23%, with NGS applications growing 24% and DSPS growing 22%.
- DNA Synthesis and Protein Solutions GrowthDNA Synthesis and Protein Solutions revenue was $61 million in the fourth quarter, up 33% year-over-year and 8% sequentially. Full-year revenue was $221.9 million, up 32%, reflecting therapeutics growth and adoption of broader DNA, protein and characterization capabilities.
- Higher Gene Shipment VolumesThe company shipped 401,000 genes in the fourth quarter and approximately 1.3 million for the full year. Annual gene-shipped volume grew 43% year-over-year, while volumes used internally more than doubled.
- AI Drug Discovery GrowthAI drug discovery orders more than doubled, while revenue grew 175% from $21.5 million in fiscal 2025 to $59.1 million in fiscal 2026. Management expects AI drug discovery to remain one of the fastest-growing product groups in fiscal 2027.
- AI Drug Discovery Customer Expansion and Repeat ActivityManagement described successive customer cohorts progressing from pilot orders, typically $10,000 to $100,000, to model-building orders often worth multiple millions of dollars, followed by recurring discovery orders typically ranging from $250,000 to $1 million in iterative cycles. Several cohorts are returning in a similar pattern, and the customer group has expanded sequentially almost every quarter.
- AI Drug Discovery Order OutlookManagement expressed confidence in achieving triple-digit percentage order growth for AI drug discovery in fiscal 2027 and said the initial $100 million revenue forecast reflects programs, the lead funnel and delivery schedules that can be forecast with high confidence, with meaningful upside beyond that assumption.
- Expanded AI Drug Discovery CapabilitiesDuring fiscal 2026, Twist expanded automation, introduced complex genes supporting the vast majority of sequences up to 7 kilobases, licensed B-Body bispecific technology and launched Twist Express Screening Antibodies. The cell-free offering delivers proteins in as few as 5 days and characterization data in as few as 8 business days.
- Protein and Characterization Capacity ExpansionOver the last 12 months, protein and antibody manufacturing capacity increased by almost 200%, while characterization capabilities expanded by 2 to 5 times depending on the assay. The company is adding another characterization lab in Oregon, which for many assays is expected to provide another 5x capacity expansion versus the end of fiscal 2026.
- NGS Applications Returned to Above-20% GrowthFourth-quarter NGS applications revenue was $65.7 million, up 24% year-over-year and 6% sequentially, driven by diagnostic customers. Full-year NGS revenue was $237.5 million, up 14%. Management said NGS growth was above 20% in the fourth quarter, consistent with prior guidance.
- MRD Express Launch and MRD OpportunityTwist launched MRD Express commercially two weeks before the call and reported strong interest. Management expects MRD Express to drive growth next year and beyond, with the ability to deliver thousands of probes for bespoke panels within 5 days and, for some processes, within 24 hours.
- Broader NGS Customer Base and New ProductsThe company served more than 700 NGS applications customers, including 190 customers adopting its products. Twist also introduced library preparation solutions for whole-genome sequencing applications, including rare disease and population genetics, which management said is a rapidly growing product group.
- Growth Across Customer IndustriesFourth-quarter therapeutics revenue was $43.9 million, up 44% year-over-year; diagnostics revenue was $45.2 million, up 23%; academic and government revenue was $16.1 million, up 21%; industry and applied revenue was $6.6 million, up 12%; and global supply partner revenue was $15 million, up 18%.
- Geographic Revenue GrowthFourth-quarter revenue grew 38% year-over-year in the Americas to $78.8 million, 12% in EMEA to $38.7 million and 28% in APAC to $9.2 million.
- Capacity and Automation InvestmentsTwist introduced approximately 30 automated systems and workflows during fiscal 2026 across protein expression, antibody characterization, MRD and NGS. The company has 10 DNA writers operating, with 2 installations planned and 4 more on order; with all 16 operating, capacity is expected to exceed 50 million pieces of DNA daily.
- Strong Liquidity and Equity FinancingThe company raised approximately $425 million in net proceeds through an equity offering and at-the-market sales. It ended fiscal 2026 with $582 million in cash, cash equivalents and short-term investments, including $424.8 million in aggregate net proceeds from the public offering and at-the-market program.
- Fiscal 2027 Revenue and Profitability GuidanceFor fiscal 2027, Twist expects total revenue of $550 million to $560 million, representing approximately 21% growth at the midpoint, gross margin of approximately 52.5% to 53%, and positive adjusted EBITDA for the full year. First-quarter fiscal 2027 revenue is expected to be $130 million to $132 million, representing approximately 26% year-over-year growth at the midpoint, with both DSPS and NGS expected to grow above 25% year-over-year.
- Long-Term Capacity and Revenue PotentialOver fiscal 2027 and fiscal 2028, the company expects approximately $150 million in capital expenditures for capacity, automation and software, plus more than $30 million in landlord-funded tenant improvements. Management said these investments are expected to expand long-term capacity to support more than $1 billion in annual revenue within existing facilities at scale.
- Nucleic Acid Therapeutics and mRNA Platform ExpansionTwist supplies DNA templates and siRNA to selected customers, including DNA used in investigational therapies in clinical trials. It expanded complex genes and research-grade DNA preparation options, offers research-grade mRNA to selected customers through early access, and has a high-throughput mRNA offering in development.
- Diversified Serviceable Addressable MarketThrough new product introductions, Twist expanded its serviceable addressable market from $2 billion to $7 billion, with line of sight to $13 billion by 2030.
TWST Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Jan 29, 2027 | 2027 (Q1) | -0.36- | -0.5 | ― | ― |
| Nov 12, 2026 | 2026 (Q4) | -0.39-0.32 | -0.45 | 28.89% (+0.13) | |
| Aug 03, 2026 | 2026 (Q3) | -0.51-0.56 | 0.33 | -269.70% (-0.89) | |
| May 04, 2026 | 2026 (Q2) | -0.48-0.71 | -0.66 | -7.58% (-0.05) | |
| Feb 02, 2026 | 2026 (Q1) | -0.42-0.50 | -0.53 | 5.66% (+0.03) | |
| Nov 14, 2025 | 2025 (Q4) | -0.41-0.45 | -0.59 | 23.73% (+0.14) | |
| Aug 04, 2025 | 2025 (Q3) | -0.520.33 | -1.47 | 122.45% (+1.80) | |
| May 05, 2025 | 2025 (Q2) | -0.55-0.66 | -0.79 | 16.46% (+0.13) | |
| Feb 03, 2025 | 2025 (Q1) | -0.63-0.53 | -0.75 | 29.33% (+0.22) | |
| Nov 18, 2024 | 2024 (Q4) | -0.71-0.59 | -0.81 | 27.16% (+0.22) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


